EGR1 and pancreatic neoplasm: Our study shows for the first time that EGR1/MDR1 axis activation promotes gemcitabine resistance in pancreatic cancer by inhibiting apoptosis.The findings demonstrate that downregulation of EGR1 expression has clinical benefits for pancreatic cancer treatment and may be a potential target for gemcitabine chemoresistance in pancreatic cancer.